Jump to content

Baxter International: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Psadaran (talk | contribs)
36 edits
m grammar
Line 80: Line 80:
{{Portalbox|Chicago|Illinois|Companies|Health and fitness}}
{{Portalbox|Chicago|Illinois|Companies|Health and fitness}}
* [http://www.Baxter.com/ Official website]
* [http://www.Baxter.com/ Official website]
* [http://carbonwhich.com/baxter-international-1922.html Baxter International Corporate Carbon Action Profile]

{{-}}
{{-}}
{{Illinois Corporations}}
{{Illinois Corporations}}

Revision as of 02:54, 31 August 2011

Baxter International Inc.
Company typePublic S&P 500 Component
NYSE: BAX
Founded1931
HeadquartersDeerfield, Illinois
Key people
Robert L. Parkinson Jr., Chairman, CEO and President
ProductsMedical supplies to treat hemophilia, kidney disease and provide intravenous therapy
RevenueIncreaseUS$12.8B (FY 2010)[1]
IncreaseUS$2.14B (FY 2010)[1]
IncreaseUS$1.42B (FY 2010)[1]
Total assetsIncreaseUS$17.5B (FY 2010)[2]
Total equityDecreaseUS$6.57B (FY 2010)[2]
Number of employees
48,500
Websitewww.Baxter.com

Baxter International Inc. (NYSE: BAX), is an American health care company with headquarters in Deerfield, Illinois.[3] The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. The company had 2009 sales of $12.6 billion, across three manufacturing divisions: BioScience (producing recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions; products for regenerative medicine; and vaccines); Medication Delivery (producing intravenous solutions and other products used in the delivery of fluids and drugs to patients, as well as inhalation anesthetics and contract manufacturing services); and Renal (providing products to treat end-stage renal disease, or irreversible kidney failure, including solutions and other products for peritoneal dialysis and hemodialysis).[4]

The company was involved in several controversies. In 2001, malfunctioning dialysis machines resulted in several deaths; in 2008 the company supplied contaminated heparin; in 2009 lethal H5N1 avian flu virus was delivered to laboratories across Europe mixed with seasonal influenza vaccines; also, the company was charged with excessive billing of Kentucky Medicaid.

Baxter International is recognized as a leader in environmental controls and commitments.[5][6][7]

History

Baxter International was founded in 1931 by Davis Baxter, a medical doctor, as a manufacturer and distributor of intravenous therapy solutions. Baxter's interest was bought out in 1935 by Ralph Falk, who established a research and development function. In 1939 the company developed a vacuum-type collection container, extending the shelf life of blood from hours to weeks. In 1953 William Graham became the company's chief executive officer, and in 1954 expanded operations outside of the United States by opening an office in Belgium. In 1956 Baxter International introduced the first functioning artificial kidney, and in 1971 became a member of the Fortune 500. Vernon Loucks became president and CEO in 1980; throughout the 1980s and 1990s the company expanded to deliver a wider variety of products and services (including vaccines, a greater variety of blood products) through acquisitions of various companies. Sales and production facilities also expanded throughout the world.[8] In 1993 the company pled guilty to a felony in relation to an anti-boycott law in the United States[9] and in 1996, the company entered into a four-way, $640 million settlement with haemophiliacs 1999 in relation to blood clotting concentrates that were infected with HIV.[10] Under pressure from shareholders due to poor performance and an unsuccessful merger, Loucks was forced to resign[9] and was replaced by Harry Kraemer, who was replaced by Robert Parkinson in 2004.[8]

Giving Back

In 2010, the Baxter Corporation instated an initiative called the “Baxter Education Advantage” Program. The program aims to offer scholarship grants of up to $15,000 to students with Hemophilia seeking higher education, offers advice on the college search process, and tools to ease the transition both into college and in preparation for the job search. In 2010, 21 students were named University Scholarship Recipients and 11 students were named Technical School Scholarship Recipients. (http://www.myeducationadvantage.com/community/scholarship-recipients.html)


Environmental activities

Baxter International is recognized as a leading company in environmental performance and reporting, having an explicit focus on environmental issues since 1976; actions included an environmental policy and manual, a series of audits, regular environmental conferences, efforts to prevent and clean up site contamination and staff dedicated to environmental improvements. In 1997, a report produced by the company indicated that changes made to reduce environmental impacts generated savings that exceeded their cost, producing a net profit. Reporting was company-wide, with a variety of aggregation and reporting, including on the company's internet and intranet sites.[5] The company was an early joiner in the "green and greedy" movement, which aims to lessen the environmental impacts of manufacturing its products while saving the company money.[6] In 2009 the company announced it had reached a variety of its environmentally friendly goals, and that it would continue to try to reduce waste, emissions, energy use and environmental incidents over the coming years.[7]

Structure

Baxter International by businessline[4][11]
Name Focus 2009 sales (In billions) Percentage total sales
BioScience Vaccines and biopharmaceuticals $5.6 45%
Medication Delivery Intravenous solutions and equipment $4.65 37%
Renal Peritoneal dialysis $2.3 18%

Sales in 2009 were 42% in the United States, 33% in Europe, 13% in Asia Pacific, 8% in Latin America and 4% in Canada. In 2009, Baxter had approximately 49,700 employees. The breakdown of regional employees in 2009 was 41% in the United States; 30% in Europe; 14% in Asia Pacific; 12% in Latin America; and 2% in Canada. In 2009, Baxter International spent $917 million on research and development.[4]

H1N1 vaccine

In June 2009, Baxter International announced it expected to have the first commercial vaccine for the H1N1 ("swine flu") influenza as early as July of the same year. The company has been one of several working with the World Health Organization and United States Centers for Disease Control and Prevention on the vaccine, and uses a cell-based rather than egg-based technology that allows a shorter production time.[12]

Controversies

2001 dialyzer flaws

On August 15, 2001, two elderly patients in Spain died within hours of receiving dialysis from Baxter products. Eventually 51 more patients would die; though the cause was unclear, the company issued a worldwide recall of two lines of filters, the sole common link between all the equipment used by the patients. Harry Kraemer, the company president at the time, apologized for the errors, shut down the factory producing filters, alerted competitors of the issue and took a 40% pay cut along with a 20% cut for other executives.[13] The company's earnings dropped by $189 million as a result of the issues. The company took quick action to reduce the impact of the event and prevent future recurrence and as a result suffered minimal damage to its reputation.[11]

2008 Chinese heparin contamination

Main article: 2008 Chinese heparin contamination

In 2008, the quality of blood thinning products produced by Baxter was brought into question when they were linked to 19 deaths in the United States.[14] Upon inspection one of the raw ingredients used by Baxter were found to be contaminated - between 5 and 20 percent - with a substance that was similar, but not identical, to the ingredient itself. The company initiated a voluntary recall, temporarily suspended the manufacture of heparin, and launched an investigation.

Investigation into the contamination has focused on raw heparin produced by Changzhou Scientific Protein Laboratories, a China based branch of Scientific Protein Laboratories, based in Waunakee, Wisconsin. Due to procedural errors Changzhou SPL's facilities was never subject to an inspection by US FDA official, as required by FDA rules. The factory's products were also never certified as safe for use in pharmaceutical products by Chinese FDA officials as Changzhou SPL was itself registered as a chemical company and not a drugs manufacturer.[15][16][17] Though Baxter was first to recall heparin because of increased adverse reactions, after the contaminant was identified and testing protocols were shared with other manufacturers globally, over a dozen other companies in nearly a dozen countries issued recalls, which linked back to certain supply points in China.

2009 avian flu contamination

In early 2009, samples of viral material supplied by Baxter International to a series of European laboratories were found to be contaminated with live Avian flu virus (Influenza A virus subtype H5N1).[18] Samples of the less harmful seasonal flu virus (subtype H3N2) were found to be mixed with the deadly H5N1 strain after a vaccine made from the material killed test animals in a lab in the Czech Republic. Though the serious consequences were avoided by the lab in the Czech Republic,[19] Baxter claimed the failed controls over the distribution of the virus were 'stringent' and there was 'little chance' of the lethal virus harming humans.[20]

2009 drug cost inflation

On July 2, 2009, Kentucky Attorney General Jack Conway announced a settlement between the state and Baxter Healthcare Corporation, a subsidiary of Baxter International, worth $2 million. The company had been inflating the cost of the intravenous drugs sold to Kentucky Medicaid, at times as much as 1300%.[21]

2010 hepatitis C infections

In 2010, a jury in Las Vegas, Nevada ordered Baxter to pay $144 million to patients who had been infected with Hepatitis C after doctors wrongly reused dirty medical supplies to administer propofol to patients. The jury granted the award, despite the fact that the label for propofol clearly states that it is for single-patient use only and that aseptic procedures should be used at all times.[22]

References

  1. ^ a b c Baxter International (BAX) annual SEC income statement filing via Wikinvest.
  2. ^ a b Baxter International (BAX) annual SEC balance sheet filing via Wikinvest.
  3. ^ "Contact Us." Baxter International. Retrieved on February 2, 2011. "Corporate address: One Baxter Parkway Deerfield, IL 60015-4625."
  4. ^ a b c "Corporate Overview". Baxter International. Retrieved 2010-11-05.
  5. ^ a b Bennett M; James P (1999). "The Evolution of Integrated Environmental Performance Evaluation and Reporting". Sustainable Measures: Evaluation and Reporting of Environmental and Social Performance. Greenleaf Pubns. pp. 253–282. ISBN 1-874719-16-0. {{cite book}}: Unknown parameter |editors= ignored (|editor= suggested) (help)CS1 maint: multiple names: authors list (link)
  6. ^ a b Adelson, G. Environment: An Interdisciplinary Anthology. Yale University Press. pp. 254–5. ISBN 0300110774. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  7. ^ a b "Baxter Cuts GHG Emissions by 21%". Environmentalleader.com. 2009-06-19. Retrieved 2009-07-03.
  8. ^ a b "History". Baxter International. Retrieved 2009-07-08.
  9. ^ a b Mintzberg, Henry (2004). Managers Not MBAs: A Hard Look at the Soft Practice of Managing and Management Development. San Francisco, Calif: Berrett-Koehler Publishers. pp. 115–6. ISBN 1-57675-275-5.
  10. ^ Feldman, EA (1999). Blood feuds: AIDS, blood, and the politics of medical disaster. Oxford University Press. pp. 49–50, 320. ISBN 0195131606. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  11. ^ a b Davis, JA (2003). "Purifying an image: Baxter International and the Dialyzer Crisis". In Feigenbaum AV (ed.). The power of management capital: utilizing the new drivers of innovation, profitability, and growth in a demanding global economy. McGraw-Hill Professional. pp. 349–364. ISBN 0070217335.
  12. ^ "Baxter to release flu vaccine in July". United Press International. 2009-06-13. Retrieved 2009-07-02.
  13. ^ Ind, Nicholas (2003). Beyond branding: how the new values of transparency and integrity are changing the world of brands. London: Kogan Page. pp. 7. ISBN 0-7494-4399-5.
  14. ^ "Heparin's Deadly Side Effects". Time magazine. 2008-11-13. Retrieved 2008-11-16. {{cite news}}: Cite has empty unknown parameter: |coauthors= (help)
  15. ^ "Contaminant Found in Blood Thinner", Washington Post (Online edition), 2008-03-05
  16. ^ "Baxter probe focuses on US-owned China plant - WSJ", Reuters, 2008-02-15
  17. ^ "China Washes Hands on Heparin Purity", Wall Street Journal (Online edition) 2008-02-27
  18. ^ "Baxter Sent Bird Flu Virus to European Labs by Error". Bloomberg L.P. 2009-02-24. Retrieved 2009-08-08.
  19. ^ "Baxter admits flu product contained live bird flu virus". The Canadian Press. 2009-02-27. Retrieved 2009-07-04. {{cite news}}: |first= missing |last= (help)
  20. ^ Jack, A (2009-03-16). "WHO mulls stricter transport of bio products". Financial Times. Retrieved 2009-06-16.
  21. ^ Tracy, B (2009-07-03). "Conway Announces Multi-Million Dollar Settlement With Drug Company". Kentucky Post. E. W. Scripps Company. Retrieved 2009-07-03.
  22. ^ Teva, Baxter Will Fight $500 Million in Damages Over Propofol, Business Week, May 8, 2010

{{{inline}}}

Retrieved from "https://en.wikipedia.org/w/index.php?title=Baxter_International&oldid=447594455"